Posts
Focal
Segmental Glomerulosclerosis is presently considered as a set of clinical
syndromes sharing a very similar common histopathologic lesion namely, focal
scarring in the glomerulus followed by fibrosis, fibrous nodules, and fibric
infiltrate. Although various causes may be involved in the pathogenesis of this
condition, the most common mechanoreceptor sites of action are the interneurons
in the optic nerve and the choroid. The choroid can be damaged due to injuries
or diseases like leukemia, lymphoma, myelodysplasia, and so on. Since these
choroid sites contain many cell types, a wide variety of cell-damage mechanisms
have been proposed to underlie Focal Segmental Glomerulosclerosis. Focal
Segmental Glomerulosclerosis is also known as nephrotic syndrome and can be
effectively addressed through surgical and non-surgical treatment options.
Increasing
prevalence of focal segmental glomerulosclerosis is expected to drive growth of
the global focal
segmental glomerulosclerosis market during the forecast period. According
to the National Organization for Rare Disorders (NORD), in the U.S., focal
segmental glomerulosclerosis is expected to affect around 7 people per million
people in the general population. However, specific rates of incidence vary
with different populations. Increasing burden of focal segmental
glomerulosclerosis has led to high demand for treatment options. Hence, these
factors are expected to drive growth of the global focal segmental
glomerulosclerosis market during the forecast period. Moreover, continuous
research and development activities for new treatment options is expected to
boost the global focal segmental glomerulosclerosis market growth over the
forecast period.
However,
high cost of kidney transplants and dialysis coupled with a lack of awareness
regarding the disease is expected to hinder the global focal segmental
glomerulosclerosis market growth over the forecast period. Among regions, North
America is expected to witness significant growth in the global focal segmental
glomerulosclerosis market during the forecast period. This is owing to the
presence of robust healthcare infrastructure and the availability of
reimbursement policies. Furthermore, Asia Pacific is expected to register a
robust growth rate over the forecast period, owing to agreements and contracts
between key market players.
Key
companies involved in the global focal segmental glomerulosclerosis market are
Sanofi S.A, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Novartis
AG, AbbVie, Inc., Retrophin, Inc., Variant Pharmaceuticals, Inc., Pfizer, Inc.,
Oraxion Therapeutics Inc., and AstraZeneca plc.
For
instance, in February 2018, Oraxion Therapeutics Inc. entered into an Option
Agreement with Aten Porous to get exclusive rights for clinical studies.
No comments:
Post a Comment